Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- 3.65 --
11/02/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 3.60 3.50 2.78%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 3.52 3.54 -0.43%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
01/26/2022 -- Results Q4 2021 3.37 3.29 2.45%
01/26/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 3.13%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
URL https://www.vrtx.com
Investor Relations URL https://investors.vrtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
29.08%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
-0.63%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
13.97%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-23.60%
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
3.37%
As of September 23, 2022.

Profile

Edit
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
URL https://www.vrtx.com
Investor Relations URL https://investors.vrtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBB 568.75M USD 7.54%
ABPRX 584.42M USD 3.41%
VGHCX 1.265B USD 2.79%
THISX 401.50M USD 2.59%
USMV 460.01M USD 1.67%
XLV 578.95M USD 1.57%
MFELX 482.48M USD 1.36%
VHT 244.68M USD 1.32%
MTUM 108.87M USD 1.16%
XBI 72.86M USD 1.11%
CNPFX 829.15M USD 0.78%
FCNKX 793.85M USD 0.76%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter VRTX Tweets